ERBB2 and urothelial carcinoma: RC48 has been approved for the treatment of HER2-positive cancer patients who have undergone at least two prior systemic chemotherapy regimens for locally advanced or metastatic gastric cancer (GC), gastroesophageal junction cancer (GEJC), and urothelial carcinoma (UC)12-15.